What Ipca Laboratories Buyers Were Betting On
NiveshIQ
NSE: IPCALAB · Healthcare
Ipca Laboratories Ltd.
₹1,949.90▲ ₹22.10 (+1.15%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on IPCALAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Ipca Laboratories Ltd.
Ipca Laboratories Limited is an integrated pharmaceutical company that manufactures and markets both active pharmaceutical ingredients (APIs) and finished dosage forms across a broad therapeutic spectrum, including anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic APIs, as well as generic and branded formulations in allergy, oncology, cardiology, dermatology, diabetes, and many other segments. The company’s revenue mix is driven primarily by its API business, which accounts for roughly 60% of total sales, while the formulation arm contributes the remaining 40%, with a strong export presence in Europe, Africa, and the Americas. In Q2 FY27, Ipca received a Reg 74(5) certificate for its Kalkine product, underscoring its compliance with international quality standards and bol
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹7,705 Cr +23.39% | ₹8,940 Cr +16.02% | ₹9,646 Cr +7.91% |
| EBITDA Margin | 17.15% | 19.31% | 20.51% |
| Net Profit | ₹547.35 Cr +16.13% | ₹737.68 Cr +34.77% | ₹1,141 Cr +54.69% |
| EPS | ₹21.57 | ₹29.08 | ₹44.98 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
What Ipca Laboratories Buyers Were Betting On
Ipca Laboratories Share Price Fall Streak and Valuation View
🔒
+ 3 more stories about Ipca Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 788 Cr, PAT ₹402 Cr, EPS ₹15.84, EBITDA margin 24.0%. Growth context: revenue YoY +20.8%, PAT YoY +72.3%, revenue QoQ +16.7%, PAT QoQ +34.4%. Street verdict: strong beat, revenue surprise +8.0%, PAT surprise +37.5%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹9, 646 Cr, PAT ₹1, 141 Cr, EBITDA margin 20.5%, EPS ₹44.98. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for IPCALAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track IPCALAB alongside your other holdings
Unlock full IPCALAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Ipca Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Ipca Laboratories Ltd. (IPCALAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Ipca Laboratories Ltd.?
Ipca Laboratories Ltd. operates in the Healthcare sector with a market capitalisation of ₹4,435,764.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.